Press Releases May 6, 2026 08:00 AM

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca to Present at Bank of America Securities Health Care Conference, Showcasing Progress in Precision Oncology

By Jordan Park ERAS

Erasca, a clinical-stage precision oncology company focused on developing therapies targeting RAS/MAPK pathway-driven cancers, announced it will present at the Bank of America Securities 2026 Health Care Conference, with management participating in a fireside chat and investor meetings. The company highlighted its mission to create novel cancer therapies by targeting the RAS/MAPK pathway.

Erasca to Present at the Bank of America Securities Health Care Conference
ERAS

Key Points

  • Erasca will present and engage with investors at a prominent healthcare conference, increasing visibility in the oncology and biotech investment community.
  • The company's focus is on precision oncology targeting RAS/MAPK pathway-driven cancers, a significant area in cancer therapeutics.
  • Erasca leverages expertise from leading pioneers and a scientific advisory board to develop novel therapies aimed at erasing cancer through pathway inhibition.

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2026 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 pm Pacific Time and will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
[email protected] 


Risks

  • As a clinical-stage biotech company, Erasca faces typical development and regulatory risks that may impact its progress and approvals.
  • Market acceptance and commercial viability of new oncology therapies remain uncertain, potentially affecting future revenues.
  • Dependence on successful clinical trials and scientific breakthroughs in the highly competitive precision oncology sector introduces execution risk.

More from Press Releases

NMI Holdings, Inc. to Participate in Upcoming Investor Conferences May 12, 2026 Fervo Energy Announces Pricing of its Upsized Initial Public Offering May 12, 2026 Titan Mining Delivers 22% Revenue Growth and Expands U.S. Critical Minerals Platform with Graphite Production May 12, 2026 Anteris Announces Results for the First Quarter of 2026 May 12, 2026 Copa Holdings Announces Monthly Traffic Statistics for April 2026 May 12, 2026